Top
| An appreciation | p. 1 |
| A personal recollection | p. 5 |
| Pathology | |
| The discovery of dopamine deficiency in the parkinsonian brain | p. 9 |
| Synchronizing activity of basal ganglia and pathophysiology of Parkinson's disease | p. 17 |
| Basal ganglia discharge abnormalities in Parkinson's disease | p. 21 |
| Bad oscillations in Parkinson's disease | p. 27 |
| Cortical muscle coupling in Parkinson's disease (PD) bradykinesia | p. 31 |
| GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons | p. 41 |
| The engrailed transcription factors and the mesencephalic dopaminergic neurons | p. 47 |
| The role of Pitx3 in survival of midbrain dopaminergic neurons | p. 57 |
| Genetic analysis of dopaminergic system development in zebrafish | p. 61 |
| Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease | p. 67 |
| The nigrostriatal DA pathway and Parkinson's disease | p. 71 |
| Relationship between axonal collateralization and neuronal degeneration in basal ganglia | p. 85 |
| Pathology associated with sporadic Parkinson's disease - where does it end? | p. 89 |
| Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease | p. 99 |
| A short overview on the role of a-synuclein and proteasome in experimental models of Parkinson's disease | p. 105 |
| The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help? | p. 111 |
| Iron and neuromelanin | |
| New face of neuromelanin | p. 119 |
| The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells | p. 125 |
| Potential sources of increased iron in the substantia nigra of parkinsonian patients | p. 133 |
| Iron and Friedreich ataxia | p. 143 |
| Genetics | |
| Nongenetic causes of Parkinson's disease | p. 147 |
| Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? | p. 153 |
| CYP450, genetics and Parkinson's disease: gene × environment interactions hold the key | p. 159 |
| Unique cytochromes P450 in human brain: implication in disease pathogenesis | p. 167 |
| Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity | p. 173 |
| Nicotine induces brain CYP enzymes: relevance to Parkinson's disease | p. 177 |
| Genetic causes of Parkinson's disease: extending the pathway | p. 181 |
| Progress in familial Parkinson's disease | p. 191 |
| Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins | p. 205 |
| Parkin and defective ubiquitination in Parkinson's disease | p. 209 |
| PINK-1 and DJ-1 - new genes for autosomal recessive Parkinson's disease | p. 215 |
| Clinical and pathologic features of families with LRRK2-associated Parkinson's disease | p. 221 |
| Molecular genetic findings in LRRK2 American, Canadian and German families | p. 231 |
| Imaging | |
| Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort | p. 235 |
| Neuroimaging in Parkinson's disease | p. 241 |
| Transcranial sonography in the early and differential diagnosis of Parkinson's disease | p. 249 |
| Models | |
| How to judge animal models of Parkinson's disease in terms of neuroprotection | p. 255 |
| Limitations of cellular models in Parkinson's disease research | p. 261 |
| The Rotenone model of Parkinsonism - the five years inspection | p. 269 |
| Controversies on new animal models of Parkinson's disease Pro and Con: the rotenone model of Parkinson's disease (PD) | p. 273 |
| Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum | p. 277 |
| ¿-Synuclein overexpression model | p. 281 |
| Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies | p. 285 |
| Clinical approaches | |
| What's new? Clinical progression and staging of Parkinson's disease | p. 305 |
| Parkinson's disease: premotor clinico-pathological correlations | p. 309 |
| Detection of preclinical Parkinson's disease along the olfactory trac(t) | p. 321 |
| The clinical approach to gait disturbances in Parkinson's disease; maintaining independent mobility | p. 327 |
| Getting around and communicating with the environment: visual cognition and language in Parkinson's disease | p. 333 |
| Cardiovascular aspects of Parkinson disease | p. 339 |
| Multiple system atrophy and autonomic failure | p. 343 |
| Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview | p. 349 |
| Sleep and wakefulness disturbances in Parkinson's disease | p. 357 |
| Neuroinflammation | |
| Parkinson's disease dementia: what's in a Lewy body? | p. 361 |
| Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10 | p. 367 |
| Role of cytokines in inflammatory process in Parkinson's disease | p. 373 |
| Neurosurgery | |
| Surgical therapy for Parkinson's disease | p. 383 |
| Deep brain stimulation for the treatment of Parkinson's disease | p. 393 |
| Deep brain stimulation in Parkinson's disease patients: biochemical evidence | p. 401 |
| Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? | p. 409 |
| L-Dopa | |
| Placebo effect and dopamine release | p. 415 |
| A new look at levodopa based on the ELLDOPA study | p. 419 |
| Thirty five years of experiencein the treatment of Parkinson's disease with levodopa and associations | p. 427 |
| Neuroprotection | |
| Concerning neuroprotective therapy for Parkinson's disease | p. 433 |
| Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model | p. 439 |
| Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression | p. 443 |
| M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease | p. 447 |
| Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety | p. 457 |
| Other treatment strategies | |
| Anti-apoptotic gene therapy in Parkinson's disease | p. 467 |
| The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors | p. 477 |
| Dystonia | |
| Pathophysiology of dystonia | p. 485 |
| Genetics of dystonia | p. 489 |
| Index | p. 497 |
| Listed in Current Contents/Life Sciences | |
| Table of Contents provided by Publisher. All Rights Reserved. |
